Browsing by Author "Dalal, Jamshed"

Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    Confronting system barriers for ST- elevation MI in low and middle income countries with a focus on India
    (Cardiological Society of India, 2018-01) Mehta, Sameer; Granger, Christopher; Grines, Cindy Lee; Jacobs, Alice; Henry, Timothy D.; Rokos, Ivan; Lansky, Alexandra; Baumbach, Andreas; Botelho, Roberto; Ferre, Alexandra; Yepes, Isaac; Salwan, Roopa; Dalal, Jamshed; Makkar, Jitendra; Bhalla, Neeraj; Mishra, Sundeep; Vijan, Vinod; Hiremath, Shirish
    Our previous research found seven specific factors that cause system delays in ST-elevation Myocardial infarction management in developing countries. These delays, in conjunction with a lack of organized STEMI systems of care, result in inefficient processes to treat AMI in developing countries. In our present opinion paper, we have specifically explored the three most pertinent causes that afflict the seven specific factors responsible for system delays. In doing so, we incorporated a unique strategy of global STEMI expertise. With this methodology, the recommendations were provided by expert Indian cardiologist and final guidelines were drafted after comprehensive discussions by the entire group of submitting authors. We expect these recommendations to be utilitarian in improving STEMI care in developing countries.
  • No Thumbnail Available
    Item
    CSI clinical practice guidelines for dyslipidemia management: Executive summary
    (Elsevier, 2024-03) Sawhney, Jitendra PS.; Ramakrishnan, Sivasubramanian; Madan, Kushal; Ray, Saumitra; Jayagopal, P Balagopalan; Prabhakaran, Dorairaj; Nair, Tiny; Zachariah, Geevar; Jain, Peeyush; Dalal, Jamshed; Radhakrishnan, Sitaraman; Chopra, Arun; Kalra, Sanjay; Mehta, Ashwani; Pancholia, Arvind K.; Kabra, Nitin K.; Kahali, Dhiman; Ghose, Tapan; Yadav, Satyavir; Kerkar, Prafulla; Yadav, Ajay; Roy, Debabrata; Das, Mrinal Kanti; Bang, Vijay H.; Rath, Pratap Chandra; Sinha, Dhurjati Prasad; Banerjee, P.S.; Yadav, Rakesh; Gupta, Rajeev
    Dyslipidemias are the most important coronary artery disease (CAD) risk factor. Proper management of dyslipidemia is crucial to control the epidemic of premature CAD in India. Cardiological Society of India strived to develop consensus-based guidelines for better lipid management for CAD prevention and treatment. The executive summary provides a bird's eye-view of the CSI: Clinical Practice Guidelines for Dyslipidemia Management published in this issue of the Indian Heart Journal. The summary is focused onthe busy clinician and encourages evidence-based management of patients and high-risk individuals. The summary has serialized various aspects of lipid management including epidemiology and categorization of CAD risk. The focus is on management of specific dyslipidemias relevant to India-raised low density lipoprotein (LDL) cholesterol, non-high density lipoprotein cholesterol (non-HDL-C), apolipoproteins, triglycerides and lipoprotein(a). Drug therapies for lipid lowering (statins, non-statin drugs and other pharmaceutical agents) and lifestyle management (dietary interventions, physical activity and yoga) are summarized. Management of dyslipidemias in oft-neglected patient phenotypes-the elderly, young and children, and patients with comorbidities-stroke, peripheral arterial disease, kidney failure, posttrans- plant, HIV (Human immunodeficiency virus), Covid-19 and familial hypercholesterolemia is also pre- sented. This consensus statement is based on major international guidelines (mainly European) and expert opinion of lipid management leaders from India with focus on the dictum: earlier the better, lower the better, longer the better and together the better. These consensus guidelines cannot replace the indi- vidual clinician judgement who remains the sole arbiter in management of the patient.
  • No Thumbnail Available
    Item
    Indian Experience with Vericiguat: A Review Based upon Case Series
    (Journal of Indian Medical Association, 2024-10) Kaul, Upendra; Dalal, Jamshed; Hiremath, Jagdish; Seth, Sandeep; Mehta, Ashwani; Juvale, Nazir; Jariwala, Pankaj V
    Heart failure (HF) is a condition that can result in repeated hospitalizations every year and can result in worsening HF (WHF). Although current pharmacological treatment for HF is fairly effective, there is a need to lower the residual risk of cardiovascular events and hospitalizations. Vericiguat, a soluble guanylate cyclase (sGC) stimulator, a new entrant, seems to present a promising therapeutic option for HF with signs of worsening, and early initiation of this therapy may be beneficial in certain patient profiles. This article explores the potential benefits of early vericiguat initiation in four patient profiles who presented with WHF.
  • Thumbnail Image
    Item
    Suspecting and diagnosing transthyretin amyloid cardiomyopathy (ATTR-CM) in India: An Indian expert consensus
    (Cardiological Society of India, 2022-12) Mohan, Jagdish Chander; Dalal, Jamshed; Chopra, Vijay Kumar; Narasimhan, Calambur; Kerkar, Prafulla; Oomman, Abraham; Fcsi, Saumitra Ray; Sharma, Anshu Rajnish; Dougall, Pankaj; Simon, Shelley; Drm, Atul Verma; Radhakrishnan, Vivek
    Transthyretin cardiac amyloidosis (ATTR-CM) is a rare and under-recognized disorder characterized by the aggregation of transthyretin-derived insoluble amyloid fibrils in the myocardium. Heterogeneity of symptoms at presentation, makes its diagnosis often delayed. An expert panel gathered on a virtual platform across India to conduct a meeting for developing a guiding tool for ATTR-CM diagnosis. The panel recommended younger age (40 years) for suspecting ATTR-CM and thick-walled non-dilated hypokinetic ventricle was considered as one of the important red flags. Electrocardiogram (ECG) and echocardiography (ECHO) findings were recommended as primary tests to raise the suspicion while nuclear scintigraphy and hematological tests were recommended to confirm the diagnosis and rule out amyloid light-chain (AL) amyloidosis. Cardiac magnetic resonance (CMR) and biopsy were recommended in case of ambiguity in the presence of red flags. Considering the lack of expert guidelines in the Indian scenario, a standardized diagnostic algorithm was also proposed.